US6402681083 - Common Stock - After market: 2.72 0 (0%)
NASDAQ:NKTR (1/31/2023, 7:00:01 PM)+0.11 (+4.21%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/amc||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||1.77%||Inst Owners||93.69%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
455 Mission Bay Blvd S
San Francisco CALIFORNIA 94158
CEO: Howard W. Robin
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual...
/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for...
SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended Septem...
Here you can normally see the latest stock twits on NKTR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.